Puma Biotechnology, Inc.

NASDAQ:PBYI

Biotechnology

Healthcare
$7.22 +2.21%

+$0.16 today

Market cap
$373.26M
Beta
1.21
P/E (TTM)
15.4
EPS (TTM)
$0.48
52W Low $3.03High $7.90

Volume 0.45M

Average 0.26M

PBYI Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Puma Biotechnology, Inc.NASDAQ: PBYI

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 42.6% from a year ago

Cash & equivalents stood at $36.2M at the end of Q1 FY2026, down 42.6% from a year earlier and up 22.2% from the prior quarter. Over 3 fiscal years it compounded at -27.0% a year.

Context

  • Cash & equivalents amounted to 18.8% of total assets at the end of Q1 FY2026, down 13.3 pp from a year earlier.
  • Cash & equivalents increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -42.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$36.2M+22.2% QoQ
Last fiscal yearDec 2025
$29.64M-57.2% YoY
Year agoMar 2025
$63.03M-42.6% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.6%——
1 year-57.2%——
3-year CAGR-27.0%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
29.64M USD
Year-over-year change
-57.2%
4-year CAGR
-17.2%

Cash & Equivalents vs competitors

How PBYI compares with its peers on the latest reported figures

  • Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -42.6% is the 6th highest of 11, against a peer median of -25.0%.
  • Cash & equivalents amounts to 18.8% of total assets for PBYI, versus a peer median of 26.6%.
PBYI Competitors
Cash & Equivalents for PBYI and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
NUVBNuvation Bio Inc.Jun 2026$258.6M USD+4.3%+17.5%34.7%
VSTMVerastem, Inc.Mar 2026$165.55M USD+40.8%+39.9%72.7%
TNGXTango Therapeutics, Inc.Sep 2026$86.84M USD+48.8%+23.3%8.4%
MGNXMacroGenics, Inc.Mar 2026$66.52M USD-54.3%-19.3%30.5%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$62.1M USD+24.5%-34.7%17.8%
ORICORIC Pharmaceuticals, Inc.Mar 2026$56.4M USD+14.3%-11.9%12.9%
PBYIPuma Biotechnology, Inc.Mar 2026$36.2M USD-42.6%-27.0%18.8%
NBPNovaBridge BiosciencesDec 2025$30.11M USD-94.0%-78.9%80.8%
BDTXBlack Diamond Therapeutics, Inc.Mar 2026$30.07M USD-69.4%-15.1%22.6%
CRDFCardiff Oncology, Inc.Mar 2026$8.54M USD-64.5%+2.2%17.4%
ONCYOncolytics Biotech Inc.Mar 2026CA$5.49M CAD-64.1%-15.1%67.3%
Peer median (excluding PBYI) —-25.0%-13.5%26.6%

Competitors are the stored peer set for PBYI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents63.13M76.2M84.59M69.22M29.64M
Short-term Investments18.98M4.87M11.35M31.75M67.89M
Net Receivables32.53M42.27M48.49M32.01M53.65M
Inventory7.11M4.53M7.08M8.72M5.52M
Other Current Assets11.43M1.95M260K3.7M4M
Total Current Assets140.02M134.28M156.19M147.66M162.69M
Property, Plant & Equipment (Net)15.77M12.51M8.65M5.09M5.56M
Goodwill00000
Intangible Assets66.13M70.61M60.87M51.13M41.39M
Long-term Investments002.09M00
Tax Assets0007.08M3.83M
Other Non-current Assets4.67M4.66M2.73M2.38M2.83M
Total Non-current Assets86.56M87.78M74.34M65.68M53.62M
Total Assets226.59M222.06M230.53M213.33M216.3M
Account Payables11.17M6.44M6.89M5.51M5.06M
Short-term Debt0034M45.33M22.52M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities11.22M13.34M43.42M15.18M16.5M
Total Current Liabilities109.59M77.48M99.38M96.11M81.25M
Long-term Debt97.09M98.31M65.66M21.72M4.71M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities6.38M12.83M5.01M1.88M0
Total Non-current Liabilities119.45M122.97M77.7M25.1M4.71M
Total Liabilities229.03M200.45M177.09M121.21M85.96M
Common Stock4K5K5K5K5K
Retained Earnings(1.37B)(1.37B)(1.35B)(1.31B)(1.28B)
Accumulated OCI(2K)0(4K)6K36K
Other Stockholders Equity0(0)000
Minority Interest00000
Total Equity(2.45M)21.61M53.44M92.13M130.34M
Total Debt116.64M114.28M111.49M74.08M28.55M
Net Debt53.51M38.08M26.91M4.86M(1.09M)

Puma Biotechnology, Inc.

NASDAQ:PBYI

Intrinsic Alpha fair value

Locked

Current Price

$7.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.